Skip to main content

Table 2 Fatty acid composition of tumour phosphatidylcholine

From: Mammary tumour development is dose-dependently inhibited by n-3 polyunsaturated fatty acids in the MMTV-neu(ndl)-YD5 transgenic mouse model

Tumour PC fatty acids

Diet

0%

3%

9%

LA (18:2n-6)

10.1 ± 1.2a

13.9 ± 0.4b

5.1 ± 0.4c

AA (20:4n-6)

16.5 ± 1.3a

10.9 ± 0.6b

6.2 ± 0.3c

DPA (22:5n-6)

0.9 ± 0.2a

0.03 ± 0.02b

0.1 ± 0.1b

ALA (18:3n-3)

0.1 ± 0.1a

0a

0.01 ± 0.01a

EPA (20:5n-3)

0.1 ± 0.1a

0.8 ± 0.1b

3.1 ± 0.2c

DPA (22:5n-3)

0.2 ± 0.04a

0.8 ± 0.1b

1.3 ± 0.6ab

DHA (22:6n-3)

1.0 ± 0.2a

1.5 ± 0.3a

2.7 ± 0.2b

Total n-6

33.0 ± 2.3a

28.4 ± 0.6a

12.5 ± 0.9b

Total n-3

1.3 ± 0.3a

3.0 ± 0.3b

7.2 ± 0.4c

n-6/n-3 ratio

24.6 ± 6.8a

9.5 ± 1.1b

1.7 ± 0.1c

Total SFA

39.3 ± 1.3a

41.5 ± 0.4a

42.1 ± 0.9a

Total MUFA

26.4 ± 2.2a

26.2 ± 0.7a

38.1 ± 1.0b

Total PUFA

34.3 ± 3.3a

31.4 ± 0.7a

19.7 ± 0.6b

P/S Ratio

0.9 ± 0.2a

0.8 ± 0.03a

0.5 ± 0.03b

  1. n = 4 for the 9% n-3 PUFA diet, n = 5 for both the 0% n-3 and 3% n-3 PUFA diets. Values in the same row not sharing the same superscript are significantly different from one another as determined by a one-way ANOVA (p < 0.05).